An experience of treatment with inhaled mannitol in pediatric cystic fibrosis patients at Moscow region
https://doi.org/10.18093/0869-0189-2019-29-4-436-442
Abstract
The objective of this study was to assess clinical efficacy and safety of inhaled mannitol (Bronchitol-Pharmaxis) in cystic fibrosis (CF) children at Moscow region. Methods. The study was designed as a single centre, observational study. Inclusion criteria were age > 9 years, confirmed diagnosis of CF and tolerability of mannitol in the BIDA test (Bronchitol Inhaled Dose Assessment). Mannitol was administered in the dose of 400 mg (10 capsules, 40 mg each) b.i.d. after inhalation of a short-acting bronchodilator. The patients also received basic therapy excluding inhaled hypertonic saline. The treatment duration was 8 weeks. Patients visited a physician at the study beginning and over 8 weeks of treatment; lung function (FEV1, FVC) and blood oxygen saturation (SatO2) were measured at each visit. Results. Lung function was stable or tended to improvement during the study. Time spent to inhalations of mannitol shortened compared to previous treatment with inhaled mucolytics and hypertonic saline. Inhaled mannitol was well-tolerated. Conclusion. The study demonstrated good tolerability and clinical efficacy of inhaled mannitol in CF children. Dry-powder formulation is also beneficial due to shorter time required for inhalation.
About the Authors
V. D. Sherman
Academician N.P.Bochkov Federal Medical Genetic Academic Center;
Moscow Regional State Referral Center for Children
Russian Federation
Russian Federation
Viktoriya D. Sherman, Candidate of Medicine, Leading Researcher, Research and Clinical Division of Cystic Fibrosis, Academician N.P.Bochkov Federal Medical Genetic Academic Center; pediatrician at Department of Cystic Fibrosis, Moscow Regional State Referral Center for Children
ul. Moskvorech'e 1, Moscow, 1115478,
ul. Kominterna 24A, build.1, Mytishchi of Moscow Region, 1141007
A. Yu. Voronkova
Academician N.P.Bochkov Federal Medical Genetic Academic Center;
Moscow Regional State Referral Center for Children
Russian Federation
Russian Federation
Anna Yu. Voronkova, Candidate of Medicine, Leading Researcher, Research and Clinical Division of Cystic Fibrosis, Academician N.P.Bochkov Federal Medical Genetic Academic Center; physician at Department of Cystic Fibrosis, Moscow Regional State Referral Center for Children
ul. Moskvorech'e 1, Moscow, 1115478,
ul. Kominterna 24A, build.1, Mytishchi of Moscow Region, 1141007
E. I. Kondrat’yeva
Academician N.P.Bochkov Federal Medical Genetic Academic Center;
Moscow Regional State Referral Center for Children
Russian Federation
Russian Federation
Elena I. Kondrat'eva, Doctor of Medicine, Professor, Head of Research and Clinical Division of Cystic Fibrosis, Academician N.P.Bochkov Federal Medical Genetic Academic Center, Head of Department of Cystic Fibrosis, Moscow Regional State Referral Center for Children
ul. Moskvorech'e 1, Moscow, 1115478,
ul. Kominterna 24A, build.1, Mytishchi of Moscow Region, 1141007
E. K. Zhekayte
Academician N.P.Bochkov Federal Medical Genetic Academic Center;
Moscow Regional State Referral Center for Children
Russian Federation
Russian Federation
Elena K. Zhekayte, Researcher, Research and Clinical Division of Cystic Fibrosis, Academician N.P.Bochkov Federal Medical Genetic Academic Center; physician at Department of Cystic Fibrosis, Moscow Regional State Referral Center for Children
ul. Moskvorech'e 1, Moscow, 1115478,
ul. Kominterna 24A, build.1, Mytishchi of Moscow Region, 1141007
A. V. Chernyak
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Aleksandr V. Chernyak, Candidate of Medicine, Head of Laboratory of Functional and Ultra-sound Investigations; Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; functional diagnostic medicine practitioner, Department of Functional and Ultrasound Diagnostics, D.D.Pletnev City Teaching Hospital, Moscow Healthcare Department
Orekhovyy bul'var 28, Moscow, 115682
SPIN-код: 9328-6440
References
1. Kapranov N.I., Kashirskaya N.Yu., eds. Cystic fibrosis. Мoscow: Medpraktica-М; 2014 (in Russian).
2. Fuchs H.J.H., Borowitz D.S., Christiansen D.H. et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozime Study Group. N. Engl. J. Med. 1994; 331 (10): 637–642. DOI: 10.1056/NEJM199409083311003.
3. Robinson M., Hemming A.L., Regnis J.A. et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 1997; 52 (10): 900–903. DOI: 10.1136/thx.52.10.900.
4. Eng P.A., Morton J., Douglass J.A. et al. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr. Pulmonol. 1996; 21 (2): 77–83. DOI: 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M.
5. Ballmann M., von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J. Cyst. Fibros. 2002; 1 (1): 35–37.
6. Elkins M.R., Robinson M., Rose B.R. et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med. 2006; 354 (3): 229–240. DOI: 10.1056/NEJMoa043900.
7. Cantor J.O., Shteyngart B., Cerreta J.M. et al. The effect of hyaluronan on elastic fiber injury in vitro and elastase-induced airspace enlargement in vivo. Proc. Soc. Exp. Biol. Med. 2000; 225 (1): 65–71.
8. Cantor J.O., Turino G.M. Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema? Chest. 2004; 125 (1): 288–292. DOI: 10.1378/chest.125.1.288.
9. Scuri M., Abraham W.M. Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep. Pulm. Pharmacol. Ther. 2003; 16 (6): 335–340. DOI: 10.1016/S1094-5539(03)00089-0.
10. Buonpensiero P., De Gregorio F., Sepe A. et al. Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Adv. Ther. 2010; 27 (11): 870–878. DOI: 10.1007/s12325-010-0076-8.
11. Ros M., Casciaro R., Lucca F. et al. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial. J. Aerosol. Med. Pulm. Drug Deliv. 2014; 27 (2): 133–137. DOI: 10.1089/jamp.2012.1034.
12. Simonova O.I., Gorinova Yu.V. [A new formulation of hypertonic saline for nebulized therapy]. Voprosy sovremennoy pediatrii. 2016; 15 (6): 631–634. DOI: 10.15690/vsp.v15i6.1662 (in Russian).
13. Patrusheva Yu.S., Bakradze M.D. [Etiology and risk factors of acute bronchiolitis in children]. Voprosy diagnostiki v pediatrii. 2012; 4 (3): 45–52 (in Russian).
14. Simonova O.I., Gorinova Yu.V., Bakradze M.D. [Efficiency of inhaled hypertonic saline in children with bronchitis and bronchiolitis]. Voprosy sovremennoy pediatrii. 2014; 13 (4): 33–39. DOI: 10.15690/vsp.v13i4.1082 (in Russian).
15. Krasovskiy S.A., Chernyak A.V., Voronkova A.Yu. et al. (eds.). [A registry of patients with cystic fibrosis in Russian Federation, 2016]. Moscow: Medpraktika-M; 2018 (in Russian).
16. Robinson M., Daviskas E., Eberl S. et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur. Respir. J. 1999; 14 (3): 678–685. DOI: 10.1034/j.1399-3003.1999.14c30.x.
17. Yaghi A., Zaman A., Dolovich M.B. The direct effect of hyperosmolar agents on ciliary beating of human bronchial epithelial cells. J. Aerosol. Med. Pulm. Drug Deliv. 2012; 25 (2): 88–95. DOI: 10.1089/jamp.2011.0914.
18. Bennett W.D., Henderson A.G., Donaldson S.H. Hydrator therapies for chronic bronchitis. lessons from cystic fibrosis. Ann. Am. Thorac. Soc. 2016; 13 (Suppl. 2): S186-190.
19. Aitken M.L., Bellon G., De Boeck K. et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am. J. Respir. Crit. Care Med. 2012; 185 (6): 645–652. DOI: 10.1164/rccm.201109-1666OC.
20. Nolan S.J., Thornton J., Murray C.S., Dwyer T. Inhaled mannitol (bronchitol) for cystic fibrosis. Paediatr. Respir. Rev. 2016; 18: 52–54. DOI: 10.1016/j.prrv.2015.12.001.
21. Middleton A., Robinson P.D., McKay K. et al. A pilot study of inhaled dry-powder mannitol during cystic fibrosis-related pulmonary exacerbation. Eur. Respir. J. 2015 45 (2): 541–544. DOI: 10.1183/09031936.00137814.
22. Amelina E., Flume P., Krasko V. et al. WS14.2. Phase 3 study of the efficacy and safety of inhaled mannitol in adults with cystic fibrosis. J. Cyst. Fibros. 2018; 17 (Suppl. 3): S25. DOI: 10.1016/s1569-1993(18)30197-8.
23. Chuchalin A.G., Aisanov Z.R., Chikina S.Y. et al. [Federal Clinical Guidelines of Russian Respiratory Society on Spirometry]. Pul'monologiya. 2014; (6): 11–24. DOI: 10.18093/0869-0189-2014-0-6-11-24 (in Russian).
24. Daviskas E., Anderson S.D., Brannan J.D. et al. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur. Respir. J. 1997; 10 (11): 2449–2454. DOI: 0.1183/09031936.97.10112449.
25. Daviskas E., Anderson S.D., Gomes K. et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology. 2005; 10 (1): 46–56. DOI: 10.1111/j.1440-1843.2005.00659.x.
26. Goldman M.D., Daviskas E., Turton J.A. et al. Inhaled mannitol improves lung function assessed by forced oscillation in a placebo controlled trial in patients with bronchiectasis. Eur. Respir. J. 2004; 24: 470–471.
Review
For citations:
Sherman V.D., Voronkova A.Yu., Kondrat’yeva E.I., Zhekayte E.K., Chernyak A.V. An experience of treatment with inhaled mannitol in pediatric cystic fibrosis patients at Moscow region. PULMONOLOGIYA. 2019;29(4):436-442. (In Russ.) https://doi.org/10.18093/0869-0189-2019-29-4-436-442
Views:
1208
Email this article 